New protease inhibitor for children. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


New protease inhibitor for children.

Posit Aware. 1997 Mar/Apr;8(2):11. Unique Identifier : AIDSLINE MED/97702739
Vazquez E; Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD; 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Abstract: At the International Conference held in Vancouver, ritonavir Norvir) and indinavir (Crixivan) were reported safe in children. Nelfinavir, found to be safe and effective in children, is expected to soon be available through expanded access to children ages 2 to 13. T-cells increased and viral load decreased in children who were treated with monotherapy for three months and who then received combination therapy with AZT or AZT/ddI. Monotherapy with either AZT or d4T (Zerit) was effective in children ages three months to six years; neutropenia was the most common side effect. Researchers have determined that combination therapy can be started early for children.
Keywords: *HIV Infections/DRUG THERAPY *HIV Protease Inhibitors/THERAPEUTIC USEKWDhivinfections/drugtherapyKWDhivproteaseinhibitors/therapeuticuse
971230
M97C1579

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .